January 29, 2010
Bioniche E. coli O157 Vaccine Recognized in Prestigious Scientific Journal

November 25, 2009
Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform

Check latest
stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Products in Development

Human Health

Bioniche has developed a technology for the treatment of human cancers. The first product developed from this technology is Urocidin^TM, a formulation of Mycobacterial Cell Wall-DNA Complex (MCC) for the treatment of bladder cancer. A Phase III clinical program is underway, consisting of two trials:

The first clinical trial was initiated in November, 2006 and is recruiting patients whose bladder cancer has not responded to treatment with the current standard therapy – BCG.

The second clinical trial will involve a comparison between Urocidin^TM and BCG as first-line therapy in patients with non muscle-invasive bladder cancer.

For more information about the Company’s clinical program in bladder cancer, please contact Bioniche Therapeutics at clinicaltrials@bioniche.com

Marketed Products

Animal Health Products

Information about Bioniche Animal Health products can be found at www.bionicheanimalhealth.com

Food Safety Products

EconicheTM is the first marketed product of the Bioniche Food Safety division.

Contact Bioniche Food Safety